Q-omics provides the consensus-scored TLCD3B profile across patient tissues and cancer cell-line models. TLCD3B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TLCD3B is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, TLCD3B RNA expression shows 17,169 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, and TGCT as cancer lineages where TLCD3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLCD3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLCD3B survival associations across molecular data types. TLCD3B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLCD3B RNA expression–survival associations across cancer types. High TLCD3B expression shows unfavorable associations in KIRP, KIRC and LIHC, but favorable associations in LGG, CESC and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TLCD3B RNA expression.
This table summarizes TLCD3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TLCD3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLCD3B shows lower tumor expression in HNSC and higher tumor expression in KIRP, LIHC, KIRC, THCA and BRCA. The KIRP box plot shows higher TLCD3B RNA expression in tumor versus normal tissue (log2 FC = +0.366, t-test p < 0.001).
This table shows molecular features associated with TLCD3B in patient tissues and cancer cell lines. In patient samples, TLCD3B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TLCD3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
